Treatment of Advanced NSCLC Patients with an Anti-Idiotypic NeuGcGM3-Based Vaccine: Immune Correlates in Long-Term Survivors

Treatment of Advanced NSCLC Patients with an Anti-Idiotypic NeuGcGM3-Based Vaccine: Immune Correlates in Long-Term Survivors

<b>Background:</b> Racotumomab-alum is an anti-idiotype vaccine targeting the NeuGcGM3 tumor-associated ganglioside. Clinical trials in advanced cancer patients have demonstrated low toxicity, high immunogenicity and clinical benefit. The goal of this study was to identify circulating bi...

Full description

Saved in:
Bibliographic Details
Main Authors: Zaima Mazorra, Haslen H. Cáceres-Lavernia, Elia Nenínger-Vinageras, Leslie M. Varona-Rodríguez, Carmen Elena Viada, Zuyen González, Nely Rodríguez-Zhurbenko, Anne-Christine Thierry, Gisela María Suarez-Formigo, Yendry Ventura-Carmenate, Petra Baumgaertner, Sara Trabanelli, Camila Jandus, Tania Crombet
Format: Article
Language:English
Published: MDPI AG 2025-05-01
Series:Biomedicines
Subjects:
non-small cell lung cancer
anti-idiotypic cancer vaccine
circulating biomarkers
Online Access:https://www.mdpi.com/2227-9059/13/5/1122
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items